Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

11.20 -0.44 (-3.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Analyst Landscape: 5 Takes On Roivant Sciences
Via Benzinga
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
From Roivant Sciences
Via GlobeNewswire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. 
From Roivant Sciences
Via GlobeNewswire
Price Over Earnings Overview: Roivant Sciences
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade. 
Via Benzinga
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2... 
Via Benzinga
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
4 Analysts Assess Roivant Sciences: What You Need To Know
Via Benzinga
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Via Benzinga
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Via Benzinga
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Via Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments. 
Via Benzinga
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
From Roivant Sciences
Via GlobeNewswire
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
From Roivant Sciences
Via GlobeNewswire
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the... 
Via Benzinga
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
From Roivant Sciences
Via GlobeNewswire
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million. 
Via Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
From Roivant Sciences
Via GlobeNewswire
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. 
Via InvestorPlace
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure... 
Via Benzinga
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.